AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $653,968 | -24.4% | 63,492 | +9.0% | 0.00% | – |
| Q2 2023 | $864,475 | +2601.5% | 58,253 | +328.3% | 0.00% | – |
| Q2 2022 | $32,000 | -80.5% | 13,600 | -41.9% | 0.00% | – |
| Q1 2022 | $164,000 | -13.7% | 23,400 | -14.0% | 0.00% | – |
| Q2 2021 | $190,000 | -48.1% | 27,200 | -34.1% | 0.00% | – |
| Q1 2021 | $366,000 | +8.0% | 41,274 | -18.4% | 0.00% | – |
| Q4 2020 | $339,000 | +229.1% | 50,601 | +151.7% | 0.00% | – |
| Q3 2020 | $103,000 | -71.0% | 20,100 | -55.0% | 0.00% | -100.0% |
| Q2 2020 | $355,000 | -73.6% | 44,700 | -71.0% | 0.00% | -75.0% |
| Q1 2020 | $1,345,000 | +301.5% | 154,261 | +96.1% | 0.00% | +300.0% |
| Q3 2019 | $335,000 | +228.4% | 78,645 | +121.1% | 0.00% | – |
| Q2 2019 | $102,000 | -47.7% | 35,572 | +32.7% | 0.00% | – |
| Q2 2018 | $195,000 | 0.0% | 26,800 | 0.0% | 0.00% | – |
| Q1 2018 | $195,000 | +72.6% | 26,800 | +94.6% | 0.00% | – |
| Q4 2017 | $113,000 | – | 13,774 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,498,838 | $22,889,355 | 11.72% |
| Knoll Capital Management, LLC | 500,000 | $4,580,000 | 7.06% |
| GENDELL JEFFREY L | 5,301,914 | $48,565,532 | 4.55% |
| COWEN AND COMPANY, LLC | 3,732,778 | $34,192,246 | 4.02% |
| Tri Locum Partners LP | 1,327,097 | $12,156,209 | 3.70% |
| Samsara BioCapital, LLC | 1,409,409 | $12,910,186 | 2.67% |
| Altium Capital Management LP | 500,000 | $4,580,000 | 2.54% |
| Vivo Capital, LLC | 3,761,438 | $34,454,772 | 2.39% |
| RTW INVESTMENTS, LP | 5,741,939 | $52,596,161 | 1.10% |
| Knott David M Jr | 291,113 | $2,667 | 1.05% |